arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Xeris Biopharma Holdings, Inc.

XERS
$8.75 ▼ -0.05 (-0.57%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
51
Health
Fair
Bearish
auto_awesome

Analytical Summary

Xeris Biopharma Holdings, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth 28.7%
Op. Margin 5.6%
ROIC 1.7%
FCF / Share $0.05
Trailing P/E
Price / Book
FCF Yield 0.6%
Debt / Equity -25.95
info Valuation on last close. End-of-day price, Sep 22, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$92.10M
↑ +28.7%
Net Income Profit after all expenses
$2.23M
— 0.0%
Operating Margin Operating profit as % of sales
5.6%
↓ -41.0% 53th
FCF / Share Free cash flow per share
$0.05
↓ -17.4%
Long-Term Debt Long-term obligations
$252.59M
↑ +14.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
49
Returns
52
Financial Health
27
Cash Quality
100

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters